HRS 5965
Alternative Names: HRS-5965Latest Information Update: 12 Dec 2024
Price :
$50 *
At a glance
- Originator Chengdu Suncadia Medicine
- Class Anti-inflammatories; Urologics
- Mechanism of Action Complement factor B modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Paroxysmal nocturnal haemoglobinuria
- Phase I Glomerulonephritis
Most Recent Events
- 04 Dec 2024 Chengdu Suncadia Medicine plans a phase III trial for Paroxysmal nocturnal haemoglobinuria in unknown location (PO, Capsule) (NCT06715943)
- 09 Nov 2024 Chengdu Suncadia Medicine plans a phase I trial in Healthy volunteers in China (PO) (NCT06684041)
- 05 Nov 2024 Chengdu Suncadia Medicine plans a phase I trial for Kidney disorders (In Volunteers) in China (PO, Capsule) (NCT06674915)